PORT WASHINGTON, N.Y., March 30, 2011 /PRNewswire/ — Premier
Heart, LLC is proud to be exhibiting the Multifunction CardioGram
at ACC 11, the 60th Annual Scientific Sessions and Expo of the
American College of Cardiology to be held April 2-5, 2011 in New
Orleans. The MCG offers completely non-invasive cardiac testing
using “power estimate as an aid to assist physicians in diagnosis”
according to its latest US FDA 510K Clearance. MCG is a
chemical and radiation-free procedure, the performance of which has
been shown in published clinical trials to be associated with
little risk of adverse events to the patient.
According to Dr. Joseph T. Shen, founder of Premier
Heart and the lead developer of Premier
Heart’s Multifunction CardioGram, “Using a computational
systems analysis approach we, as physicians, now have a method that
analyzes and compares raw electro-cardiac data to help identify
significant CAD and which has been shown in multiple studies to
assist in accurate detection the presence of significant coronary
artery disease requiring intervention with improved specificity and
negative predictive values. MCG’s advanced technology works
by sampling a signal from two left ventricular leads (V5 and II)
and performing a series of digital signal analysis operations. The
operations produce a sequence of indexes, which quantify
abnormalities in the mathematically transformed electro-cardiac
data. This information is transferred via the Internet to
Premier Heart in New York, where it is compared to a database of
over 40,000 patients. A numeric score is assigned based on
this analysis representing the likelihood and severity of CAD.
This score is reported back to physicians within minutes to
aid in detection and diagnosis in a point of care setting.”
Premier Heart’s MCG is being used by many physicians in
the
‘/>”/>
SOURCE
